December 22, 2021 Press release - Regulatory Targovax ASA – Registration of share capital increase pertaining to the Rights Issue
December 20, 2021 Press release - Non-regulatory Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
December 15, 2021 Press release - Regulatory Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
December 14, 2021 Press release - Regulatory Targovax ASA – The subscription period for the rights issue expires today
December 13, 2021 Press release - Non-regulatory Targovax to present at DNB’s 12[th] Nordic Healthcare Conference
December 10, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
December 10, 2021 Press release - Regulatory Targovax ASA – Last day of trading in subscription rights
December 10, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
December 1, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
November 30, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
November 30, 2021 Press release - Regulatory Targovax ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates
November 30, 2021 Press release - Regulatory Targovax ASA – Commencement of the subscription period for the rights issue
November 29, 2021 Press release - Regulatory Targovax ASA – Approval and publication of the prospectus for the rights issue
November 25, 2021 Press release - Regulatory Targovax ASA – Rights issue approved by the extraordinary general meeting
November 24, 2021 Press release - Regulatory Targovax ASA – Updated key information relating to the preferential rights issue
November 24, 2021 Press release - Regulatory Targovax ASA – Terms of the fully underwritten rights issue
November 18, 2021 Press release - Non-regulatory Targovax invites to webcast presentation in Norwegian
November 9, 2021 Press release - Non-regulatory Targovax announces two posters at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 4, 2021 Press release - Regulatory Targovax ASA – Key information relating to the preferential rights issue
November 4, 2021 Press release - Regulatory Targovax ASA – Notice of extraordinary general meeting – Fully underwritten rights issue
October 27, 2021 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2021 results, Thursday 4 November
October 22, 2021 Press release - Non-regulatory Targovax invites to webcast presentation on Xtrainvestor
October 6, 2021 Press release - Non-regulatory Targovax ASA: Two abstracts accepted at the SITC Congress
September 30, 2021 Press release - Non-regulatory Targovax ASA appoints Ola Melin as Head of Manufacturing
September 24, 2021 Press release - Non-regulatory Targovax granted European Patent for ONCOS-102 in combination with chemotherapy
September 16, 2021 Press release - Non-regulatory Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
August 27, 2021 Press release - Non-regulatory Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress
August 18, 2021 Press release - Regulatory Targovax ASA: second quarter and first half year 2021 results
August 16, 2021 Press release - Non-regulatory Targovax to present at upcoming scientific conferences
August 9, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August
July 9, 2021 Press release - Regulatory Targovax announces resignation of Chief Financial Officer, Torbjørn Furuseth
July 1, 2021 Press release - Regulatory Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
June 28, 2021 Press release - Regulatory Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition
June 22, 2021 Press release - Regulatory Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 17, 2021 Press release - Regulatory Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 14, 2021 Press release - Regulatory Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
June 10, 2021 Press release - Regulatory Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
May 26, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following the settlement of RSUs
May 21, 2021 Press release - Non-regulatory Targovax to present at upcoming investor and scientific conferences
May 19, 2021 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders in connection with settlement of RSUs
May 18, 2021 Press release - Regulatory Targovax ASA: Resolution to increase the share capital following exercise of RSUs
April 27, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s first quarter 2021 results, Thursday 6 May
March 18, 2021 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
March 9, 2021 Press release - Non-regulatory Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors
March 8, 2021 Press release - Non-regulatory Targovax to present and attend at upcoming investor and scientific conferences
March 4, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
March 1, 2021 Press release - Regulatory Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
February 24, 2021 Press release - Non-regulatory Targovax: Proposal for Remuneration Guidelines for Board and Executive Management
February 23, 2021 Press release - Non-regulatory Continued survival benefit in Targovax’s ONCOS-102 trial in mesothelioma at the 21-month follow-up
February 18, 2021 Press release - Non-regulatory Reminder: Invitation to Targovax’s Capital Markets Day 18 February 2021
February 15, 2021 Press release - Non-regulatory Targovax receives Fast-Track designation for ONCOS-102
February 11, 2021 Press release - Non-regulatory Agenda for Targovax’s Capital Markets Day 18 February 2021
February 10, 2021 Press release - Non-regulatory Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
February 9, 2021 Press release - Non-regulatory SOTIO has stopped collaboration trial with the dendritic cell vaccine DCVAC in combination with ONCOS-102
January 11, 2021 Press release - Non-regulatory Targovax to present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 6, 2021 Press release - Non-regulatory Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
